Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Nicholas, Iannotti"'
Autor:
Enriqueta Felip, Mario Sznol, Harriet Kluger, Erin Filbert, Valentina Boni, Montaser Shaheen, Nicholas Iannotti, Delvys Rodriguez-Abreu, Maria Gonzalez-Cao, Alfonso Berrocal, Ralph Hauke, Lynn Schuchter, Gerald Linette, Sarah Weiss, Miguel-Ángel Berciano-Guerrero, Ana Maria Arance, Apar Kishor Ganti
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/486cee47556042ac976f547e0220656d
Autor:
Jaafar Bennouna, Guy Jerusalem, Karen Kelly, David Spigel, Marcis Bajars, Claire F Verschraegen, Edward F McClay, Nicholas Iannotti, Charles H Redfern, Franklin L Chen, John C Morris, Hans Juergen Grote, Dongli Zhou, Neru Munshi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Introduction Avelumab, an antiprogrammed death ligand-1 antibody, is approved as a monotherapy for treatment of metastatic Merkel cell carcinoma and advanced urothelial carcinoma, and in combination with axitinib for advanced renal cell carcinoma. We
Externí odkaz:
https://doaj.org/article/e6b6f8200ed4438aa9844cca535c6384
Autor:
Borys Hrinczenko, Nicholas Iannotti, Sanjay Goel, David Spigel, Howard Safran, Matthew H Taylor, Jaafar Bennouna, Deborah J Wong, Karen Kelly, Claire Verschraegen, Marcis Bajars, Juliane Manitz, Mary Ruisi, James L Gulley
Publikováno v:
Future Oncology. 18:1333-1342
Background: This study examined patients with advanced non-small-cell lung cancer who received long-term avelumab (anti-PD-L1) in a large phase Ib trial (JAVELIN Solid Tumor). Methods: Patients receiving >2 years of avelumab were reviewed and explora
Autor:
Andrew Leonard Laccetti, Gurkamal S. Chatta, Nicholas Iannotti, Christos Kyriakopoulos, Karen Villaluna, Ronan Le Moigne, Alessandra Cesano
Publikováno v:
Journal of Clinical Oncology. 41:179-179
179 Background: EPI-7386 is a next generation aniten designed to inhibit androgen receptor (AR) activity by binding to the N-terminal domain (NTD) of the AR while effectively blocking transcription despite AR resistance mechanisms driven by the ligan
Autor:
Russell Kent Pachynski, Nicholas Iannotti, Andrew Leonard Laccetti, Bradley Curtis Carthon, Kim N. Chi, Matthew Raymond Smith, Nicholas J. Vogelzang, Wilson Tu, Edmond Michael Kwan, Alexander William Wyatt, Karen Villaluna, Brett Younginger, Alessandra Cesano
Publikováno v:
Journal of Clinical Oncology. 41:177-177
177 Background: EPI-7386 is a next generation aniten, a novel class of compounds designed to inhibit androgen receptor (AR) activity by binding to the N-terminal domain. Preclinical data supports disruption of AR regulated gene transcription even in
Autor:
Montaser Shaheen, Lynn M. Schuchter, Delvys Rodriguez-Abreu, Erin L. Filbert, Maria Gonzalez-Cao, Apar Kishor Ganti, Ralph J. Hauke, Enriqueta Felip, Nicholas Iannotti, Ana Arance, Sarah A. Weiss, Harriet M. Kluger, Valentina Boni, Mario Sznol, Alfonso Berrocal, Miguel-Ángel Berciano-Guerrero, Gerald P. Linette
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundA significant number of melanoma patients treated with anti-PD-1 alone or in combination with anti-CTLA-4 have transient or no response to treatment. Sotigalimab is a CD40 agonist antibody with unique epitope specificity and Fc receptor bin
Autor:
Grace K. Dy, Iryna Teslenko, Sharon Lu, Eddie Thara, Yongqiang Tang, Afshin Dowlati, David R. Spigel, Nithya Iyer Singh, Suresh S. Ramalingam, Thomas E. Stinchcombe, Basir Haque, Nicholas Iannotti, Mark M. Awad
Publikováno v:
Cancer. 128(1)
Background Poly(ADP-ribose) polymerase (PARP) inhibitors may synergize with programmed cell death receptor-1 (PD-1) inhibitors to enhance adaptive and innate antitumor immune responses. In the phase 2 JASPER study (NCT04475939), the PARP inhibitor ni
Autor:
Karen Kelly, Dongli Zhou, Jaafar Bennouna, Franklin Chen, Guy Jerusalem, John C. Morris, Ding Wang, Claire F. Verschraegen, Marcis Bajars, Edward F. McClay, Neru Munshi, David R. Spigel, Hans Juergen Grote, Janice M. Mehnert, Matthew H. Taylor, James L. Gulley, Nicholas Iannotti, Charles H. Redfern
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
IntroductionAvelumab, an antiprogrammed death ligand-1 antibody, is approved as a monotherapy for treatment of metastatic Merkel cell carcinoma and advanced urothelial carcinoma, and in combination with axitinib for advanced renal cell carcinoma. We
Autor:
Karen Kelly, Isabell Speit, Janice M. Mehnert, Anja H. Loos, Nicholas Iannotti, Helga Koch, Manish R. Patel, Deborah J. Wong, James L. Gulley, Matthew H. Taylor, Jeffrey R. Infante
Publikováno v:
Cancer. 124:2010-2017
Author(s): Kelly, Karen; Infante, Jeffrey R; Taylor, Matthew H; Patel, Manish R; Wong, Deborah J; Iannotti, Nicholas; Mehnert, Janice M; Loos, Anja H; Koch, Helga; Speit, Isabell; Gulley, James L | Abstract: BackgroundAntibodies targeting the program
Autor:
M. Olivo, David R. Spigel, J. Kim, Enriqueta Felip, Nobuyuki Katakami, Nicholas Iannotti, Miyako Satouchi, Hiroshi Nokihara, Fabrice Barlesi, Matthew Guo, James Chih-Hsin Yang
Publikováno v:
Annals of Oncology
Background Eribulin is a microtubule dynamics inhibitor with a novel mechanism of action. This phase 3 study aimed to compare overall survival (OS) in patients with heavily pretreated non-small cell lung cancer (NSCLC) receiving eribulin to treatment